Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming when stakes are high
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
October 17, 2025
Respiratory Video Recap—October 17, 2025
October 17, 2025
Lucid Diligence Brief: EVOQ x Sanofi collaboration
October 17, 2025
Respiratory Today—October 17, 2025
October 16, 2025
Cell and Gene Therapy Video Recap – October 16, 2025
October 16, 2025
Cardiovascular Today – October 16, 2025
October 16, 2025
Rare Disease Today – October 16, 2025
October 16, 2025
Cell and Gene Therapy Today – October 16, 2025
October 16, 2025
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040
October 15, 2025
Lucid Diligence Brief: Verily UCHealth AI collaboration
October 15, 2025
Immunology Today: Zenas MS Deal, J&J FDA Approvals (Oct 8–15, 2025)
October 15, 2025